HomeQuestion

How should a CAC score of 350 influence risk stratification in an asymptomatic primary‑prevention patient with borderline‑to‑intermediate ASCVD risk?

Join the Discussion

Discuss the cases and questions guidelines don't cover.

Related Questions

Would you defer or opt for plavix loading in a patient already on DAPT presenting with NSTEMI attributed to likely non-ischemic myocardial injury but with known CAD?

Would you consider transitioning patients older than 75 years of age with coronary disease from statins and/or other lipid-lowering agents to PCSK9 inhibitors given concerns for polypharmacy, provided their LDL levels remain at or below goal?

When do you think physicians should seriously consider prescribing PCSK9 inhibitors for the prevention of heart attack and stroke in people with ASCVD or diabetes, based on the results of the VESALIUS-CV trial?

What are your preferred lipid-lowering agents and target LDL reduction goal following initiation of therapy for patients with familial hyperlipidemia without underlying CAD?

Do you recommend against use of enteric coated aspirin as opposed to plain aspirin for secondary prevention of stroke or MI?

Evidence Meets Expertise

For Physicians

Mednet AI
Community

Company

About
Careers
Publications
Blog

Support

FAQs
Code of Conduct
AI Community Guidelines
Contact Us
Programs

Legal

Privacy Policy
Terms of Service

© 2026 Mednet Inc. All rights reserved.